Related Experiment Video
Updated: Jun 15, 2026

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function
Jung Pyo Lee1, Nam Ju Heo, Kwon Wook Joo
1Seoul National University Kidney Research Institute, Seoul, Korea.
Insights
Chronic kidney disease (CKD) is common after liver transplants, especially in HBV patients. Careful use of calcineurin inhibitors (CNIs) is crucial to prevent kidney damage in liver recipients.
Area of Science:
- Nephrology
- Hepatology
- Transplantation Medicine
Background:
- Chronic kidney disease (CKD) is a frequent complication post-liver transplantation (LTx).
- Risk factors for CKD after LTx require evaluation, particularly in Asian populations where hepatitis B virus (HBV) is a leading cause of liver disease.
Purpose of the Study:
- To identify and analyze risk factors for CKD development in Korean liver transplant recipients.
- To evaluate the impact of pre-transplant kidney function on post-transplant renal outcomes.
Main Methods:
- Analysis of 431 Korean LTx recipients from 1997-2008.
- CKD defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) for ≥3 months.
- Multivariate Cox regression used to identify risk factors.
Main Results:
- Eighty percent of patients had HBV-related liver disease.
- Recipients with high pre-LTx eGFR (>or=60 mL/min/1.73 m(2)) showed significant decline, while those with low eGFR (<30 mL/min/1.73 m(2)) improved.
- Risk factors for CKD included older age, cyclosporine, post-LTx acute renal failure (ARF), CNI nephrotoxicity, low pre-LTx eGFR, hepatorenal syndrome, proteinuria, and high Child-Pugh/MELD scores.
Conclusions:
- Calcineurin inhibitor (CNI) nephrotoxicity is a significant contributor to CKD post-LTx, especially in HBV recipients.
- Judicious use of CNIs is recommended to prevent kidney dysfunction in liver transplant recipients.
Background:
Chronic kidney disease (CKD) develops frequently after liver transplantation (LTx), and it is important to identify and correct risk factors that negatively affect kidney function. Risk factors have not been well evaluated in Asian countries where hepatitis B virus (HBV) infection is a dominant cause.
Methods:
Four hundred thirty-one Korean recipients who underwent LTx between 1997 and 2008 were analysed. CKD was defined as a sustained decrease in estimated glomerular filtration rate (eGFR) of <60 (mL/min/1.73 m(2)) for at least three consecutive months using an abbreviated Modification in Renal Disease (MDRD) formula.
Results:
Eighty percent of the patients had HBV-related underlying diseases. The recipients whose pretransplant eGFR had been low (<30 mL/min/1.73 m(2)) improved their renal function after LTx, but significant functional decline occurred in recipients whose pretransplant eGFR was high (>or=60 mL/min/1.73 m(2)). A multivariate Cox regression analysis revealed that the overall risk of CKD development (eGFR < 60 mL/min/1.73 m(2)) was associated with old age of recipients, cyclosporine, posttransplant acute renal failure (ARF), cause [calcineurin inhibitor (CNI) nephrotoxicity] and severity of posttransplant ARF, low pretransplant eGFR, pretransplant hepatorenal syndrome, pretransplant proteinuria, high Child-Pugh score and high Model for End-Stage Renal Disease (MELD) score. Especially in recipients whose pre-operative eGFR was high (>or=60 mL/min/1.73 m(2)), rapid progression of kidney disease was associated with high tacrolimus level, non-HBV disease, posttransplant ARF, cause (CNI nephrotoxicity) and severity of posttransplant ARF and Child-Pugh score. CNI toxicity and focal segmental sclerosis, but not immune-complex disease, were revealed as significant contributors to CKD after LTx in HBV recipients.
Conclusion:
Judicious use of CNIs should be applied to liver recipients to prevent kidney dysfunction.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
